BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther. 2008;6:1347-1355. [PMID: 19018688 DOI: 10.1586/14779072.6.10.1347] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag 2009;5:411-27. [PMID: 19475778 DOI: 10.2147/vhrm.s4235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
2 Udani SM, Koyner JL. Effect of blood pressure lowering on markers of kidney disease progression. Curr Hypertens Rep 2009;11:368-74. [PMID: 19737454 DOI: 10.1007/s11906-009-0061-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Kalaitzidis RG, Elisaf MS. Treatment of Hypertension in Chronic Kidney Disease. Curr Hypertens Rep 2018;20. [DOI: 10.1007/s11906-018-0864-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
4 Coca A, Mazón P, Aranda P, Redón J, Divisón JA, Martínez J, Calvo C, Galcerán JM, Barrios V, Coll ARI. Role of dihydropyridinic calcium channel blockers in the management of hypertension. Expert Review of Cardiovascular Therapy 2014;11:91-105. [DOI: 10.1586/erc.12.155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
5 Galceran J, Plana J, Felip A, Pou G, Vila J, Sobrino J. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers. Expert Rev Cardiovasc Ther 2010;8:751-7. [PMID: 20528630 DOI: 10.1586/erc.10.48] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ott C, Schneider MP, Raff U, Ritt M, Striepe K, Alberici M, Schmieder RE. Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. Br J Clin Pharmacol. 2013;75:129-135. [PMID: 23240643 DOI: 10.1111/j.1365-2125.2012.04336.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
7 Fogari R, Mugellini A, Circelli M, Cremonesi G. Combination delapril/manidipine as antihypertensive therapy in high-risk patients. Clin Drug Investig 2011;31:439-53. [PMID: 21627336 DOI: 10.2165/11589000-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Martínez Martín FJ. Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. Expert Rev Cardiovasc Ther. 2009;7:863-869. [PMID: 19589122 DOI: 10.1586/erc.09.53] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
9 Liberopoulos EN, Moutzouri E, Rizos CV, Barkas F, Liamis G, Elisaf MS. Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia. J Cardiovasc Pharmacol Ther. 2013;18:113-118. [PMID: 23113965 DOI: 10.1177/1074248412463611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Ptinopoulou AG, Pikilidou MI, Lasaridis AN. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. Hypertens Res 2013;36:91-101. [PMID: 23051659 DOI: 10.1038/hr.2012.157] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
11 Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010;32:192-7. [PMID: 20199181 DOI: 10.3109/08860220903541135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
12 Robles NR, Fici F, Grassi G. Dihydropyridine calcium channel blockers and renal disease. Hypertens Res 2017;40:21-8. [DOI: 10.1038/hr.2016.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
13 Li X, Yang MS. Effects of T-type calcium channel blockers on renal function and aldosterone in patients with hypertension: a systematic review and meta-analysis. PLoS One. 2014;9:e109834. [PMID: 25330103 DOI: 10.1371/journal.pone.0109834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kohlmann O Jr, Roca-Cusachs A, Laurent S, Schmieder RE, Wenzel RR, Fogari R. Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. Adv Ther 2009;26:313-24. [PMID: 19330493 DOI: 10.1007/s12325-009-0015-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
15 Rizos CV. Manidipine: A different dihydropyridine. WJH 2011;1:3. [DOI: 10.5494/wjh.v1.i1.3] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
16 Reboldi G, Gentile G, Angeli F, Verdecchia P. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Review of Cardiovascular Therapy 2014;7:1349-61. [DOI: 10.1586/erc.09.133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
17 Martinez-martin FJ, Macias-batista A, Comi-diaz C, Rodriguez-rosas H, Soriano-perera P, Pedrianes-martin P. Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with Metabolic Syndrome: The MARCADOR Study. Clinical Drug Investigation 2011;31:201-12. [DOI: 10.2165/11587590-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]